NEW YORK, NY, USA I February 8, 2018 I Vyera Pharmaceuticals, LLC (Vyera) announced the initiation of a Phase 1 single ascending dose (SAD) study of TUR-006, a proprietary drug candidate with a novel dihydrofolate reductase (DHFR) inhibitor which Vyera discovered and is developing for the treatment of toxoplasmosis.  Health Canada, the government agency that oversees pharmaceuticals and clinical research in Canada, granted a No Objection Letter (NOL) to Vyera on December 21, 2017, in response to Vyera’s submission of a Clinical Trial Application. Health Canada’s NOL gives permission for Vyera to proceed with dosing the first human subjects in its Phase 1 investigation of TUR-006. Vyera intends to begin a multiple ascending dose study pending satisfactory completion of the SAD study.

Vyera’s drug discovery program identified TUR-006 through its efforts to create a toxoplasmosis treatment that will be more potent and better tolerated than existing options. Toxoplasmosis, a parasitic infection caused by Toxoplasma gondii (T. gondii), is a leading cause of death attributed to food-borne illness in the United States. The Centers for Disease Control and Prevention (CDC) identified toxoplasmosis as one of five neglected parasitic infections targeted for public health action. TUR-006 is a new chemical entity and a potent DHFR inhibitor, which has demonstrated efficacy in cell-based and animal models of acute toxoplasmosis. Vyera has developed TUR-006 as a solid, oral dosage form, which is scheduled for further exploration in upcoming clinical investigations.

About Vyera Pharmaceuticals 
Vyera Pharmaceuticals is a drug company with offices in the United States and Switzerland. Vyera is committed to developing and commercializing treatments that address serious and neglected diseases with high unmet needs. Vyera supports programs that offer financial assistance to patients in need and gives discounts to organizations that provide care to underserved populations. Vyera’s Research & Development efforts focus on developing novel treatment options for toxoplasmosis and other rare or serious health conditions.

SOURCE: Vyera Pharmaceuticals